Misonix (NASDAQ:MSON) Stock Crosses Above 200 Day Moving Average of $22.65

Misonix, Inc. (NASDAQ:MSON)’s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $22.65 and traded as high as $25.29. Misonix shares last traded at $25.20, with a volume of 22,647 shares changing hands.

Several research analysts recently commented on the stock. BTIG Research cut shares of Misonix from a “buy” rating to a “neutral” rating in a report on Monday, August 2nd. Craig Hallum cut shares of Misonix from a “buy” rating to a “hold” rating and increased their target price for the stock from $23.00 to $28.00 in a report on Friday, July 30th. Finally, Canaccord Genuity cut shares of Misonix from a “buy” rating to a “hold” rating and increased their target price for the stock from $23.00 to $28.00 in a report on Friday, July 30th.

The company has a quick ratio of 1.92, a current ratio of 2.61 and a debt-to-equity ratio of 0.29. The company’s fifty day moving average is $25.67 and its 200 day moving average is $22.66. The firm has a market cap of $437.17 million, a price-to-earnings ratio of -29.89 and a beta of 1.40.

Misonix (NASDAQ:MSON) last posted its quarterly earnings results on Thursday, September 2nd. The medical equipment provider reported ($0.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.02). Misonix had a negative return on equity of 10.36% and a negative net margin of 19.55%. The firm had revenue of $19.69 million for the quarter.

A number of hedge funds and other institutional investors have recently bought and sold shares of MSON. BNP Paribas Arbitrage SA raised its position in Misonix by 41.8% during the first quarter. BNP Paribas Arbitrage SA now owns 3,979 shares of the medical equipment provider’s stock worth $78,000 after acquiring an additional 1,173 shares in the last quarter. Barclays PLC raised its position in Misonix by 159.0% during the first quarter. Barclays PLC now owns 10,045 shares of the medical equipment provider’s stock worth $197,000 after acquiring an additional 6,166 shares in the last quarter. Private Advisor Group LLC bought a new position in shares of Misonix in the second quarter valued at about $214,000. Alliancebernstein L.P. bought a new position in shares of Misonix in the second quarter valued at about $220,000. Finally, DAVENPORT & Co LLC raised its position in shares of Misonix by 3.9% in the second quarter. DAVENPORT & Co LLC now owns 13,295 shares of the medical equipment provider’s stock valued at $295,000 after purchasing an additional 500 shares during the period. 40.52% of the stock is currently owned by hedge funds and other institutional investors.

Misonix Company Profile (NASDAQ:MSON)

Misonix, Inc is a medical device company, which engages in the design, development, manufacture and marketing of therapeutic ultrasonic medical devices. It operates through the following segments: Surgical and Wound. The Surgical segment consists of BoneScalpel and SonaStar products. The Wound segment consists of SonicOne, TheraSkin and Therion products.

Featured Story: Why is the ex-dividend date different from the record date?

Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.